CC
MDGL icon

Centiva Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

Centiva Capital’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,000
Closed -$3.31M – 1865
2025
Q1 		$3.31M Buy
+10,000
New +$3.29M 0.1% 101
2024
Q2 		– Sell
-1,000
Closed -$267K – 2331
2024
Q1 		$267K Buy
+1,000
New +$236K 0.01% 1309

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Centiva Capital's MDGL Position: Q2 2023 in Review

Centiva Capital sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2023, closing a stake of 7,142 shares — an estimated $1.73M sold.

Centiva Capital first reported a position in MDGL in Q1 2023 and held it in 1 quarter. The position peaked at $1.73M in Q1 2023. 208 funds tracked by Wall St. Rank hold MDGL as of Q2 2023.

  • Centiva Capital reported no remaining Madrigal Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Centiva Capital sold 7,142 Madrigal Pharmaceuticals shares in Q2 2023, an estimated $1.73M.
  • Centiva Capital first reported a position in Madrigal Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Centiva Capital's Madrigal Pharmaceuticals position peaked at $1.73M in Q1 2023.
  • 208 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2023.

Based on Centiva Capital's 13F filing for Q2 2023, filed 14 Aug 2023.